GeneOne Life Science진원생명과학

GeneOne Life Science is still deeply loss-making, with trailing revenue falling and heavy borrowings, and its share price down about 76% over the past year.

The company reports trailing twelve-month revenue of ₩12.4B against an operating loss of ₩39.9B and a net loss of ₩48.9B as of H1 2026. Borrowings of ₩29.6B exceed cash of ₩0.4B, and free cash flow was negative ₩13.3B. The share price closed at ₩2,670 on 2026-10-16, with a market capitalisation of about ₩48.5B.

What stands out

• Revenue has declined each year since 2023, from ₩40.2B in 2023 to ₩23.0B in 2025, and trailing revenue is ₩12.4B.
• Operating margin is about -323% on a trailing basis, and the company has posted operating losses in every year shown from 2021 to 2026.
• Liabilities are 249% of equity and cash is small relative to borrowings, which the data flags as a balance sheet strain.
• Recent filings are dominated by a rights offering (paid-in capital increase), shareholder meeting notices, and a decision on acquiring the company's own convertible bonds before maturity.
• Foreign ownership fell from 1.5% to 0% over the last 60 days, and 20-day flows show net foreign selling of about ₩1.2B.

What to watch

• Details and timing of the rights offering and its dilution effect on existing shareholders, as set out in the amended filings.
• The shareholder meeting agenda and record date, plus any listing committee review outcome; the data notes an extension of a listing committee review deadline.
• Whether revenue and cash flow improve enough to address the borrowings, and whether the filing for unfaithful disclosure designation leads to further consequences; the news feed contained no recent headlines to explain these items.